Beilstein Journal of Organic Chemistry

A divergent asymmetric approach to aza-spiropyran derivative and (1*S*,8a*R*)-1-hydroxyindolizidine

Jian-Feng Zheng, Wen Chen, Su-Yu Huang, Jian-Liang Ye and Pei-Qiang Huang*

Full Research Paper

Open Access

Address:
Department of Chemistry and Key Laboratory for Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China

Email:
Jian-Feng Zheng - zjf485@xmu.edu.cn; Wen Chen - thereyoube@163.com; Su-Yu Huang - hsy8872968@126.com; Jian-Liang Ye - yejl@xmu.edu.cn; Pei-Qiang Huang* - pqhuang@xmu.edu.cn

* Corresponding author

Beilstein Journal of Organic Chemistry **2007**, 3, No. 41.
doi:10.1186/1860-5397-3-41

Received: 23 September 2007
Accepted: 08 November 2007
Published: 08 November 2007

Abstract

Background

Spiroketals and the corresponding aza-spiroketals are the structural features found in a number of bioactive natural products, and in compounds possessing photochromic properties for use in the area of photochemical erasable memory, self-development photography, actinometry, displays, filters, lenses of variable optical density, and photomechanical biomaterials etc. And (1*R*,8a*S*)-1-hydroxyindolizidine (**3**) has been postulated to be a biosynthetic precursor of hydroxylated indolizidines such as (+)-lentiginosine **1**, (−)-2-epilentiginosine **2** and (−)-swainsonine, which are potentially useful antimetastasis drugs for the treatment of cancer. In continuation of a project aimed at the development of enantiomeric malimide-based synthetic methodology, we now report a divergent, concise and highly diastereoselective approach for the asymmetric syntheses of an aza-spiropyran derivative **7** and (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**).

Results

The synthesis of aza-spiropyran **7** started from the Grignard addition of malimide **4**. Treatment of the THP-protected 4-hydroxybutyl magnesium bromide with malimide **4** at −20°C afforded *N*,*O*-acetal **5a** as an epimeric mixture in a combined yield of 89%. Subjection of the diastereomeric mixture of *N*,*O*-acetal **5a** to acidic conditions for 0.5 h resulted in the formation of the desired functionalized aza-spiropyran **7** as a single diastereomer in quantitative yield. The stereochemistry of the aza-spiropyran **7** was determined by NOESY experiment. For the synthesis of *ent*-**3**, aza-spiropyran **7**, or more conveniently, *N*,*O*-acetal **5a**, was converted to lactam **6a** under standard reductive dehydroxylation conditions in 78% or 77% yield. Reduction of lactam **6a** with borane-dimethylsulfide provided pyrrolidine **8** in 95% yield. Compound **8** was then converted to 1-hydroxyindolizidine *ent*-**3** via a four-step procedure, namely, *N*-debenzylation/*O*-mesylation/Boc-cleavage/cyclization, and *O*-debenzylation. Alternatively, amino alcohol **8** was mesylated and the resultant mesylate **12** was subjected to hydrogenolytic conditions, which gave (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**) in 60% overall yield from **8**.

Conclusion

By the reaction of functionalized Grignard reagent with protected (*S*)-malimide, either aza-spiropyran or (1*S*,8a*R*)-1-hydroxyindolizidine skeleton could be constructed in a concise and selective manner. The results presented herein constitute an important extension of our malimide-based synthetic methodology.

Background

Spiroketals of general structure **A** (Scheme 1) constitute key structural features of a number of bioactive natural products isolated from insects, microbes, fungi, plants or marine organisms. [1-3] The corresponding aza-spiroketal (cf: general structure **B**) containing natural products, while less common, are also found in plants, shellfish and microbes.[4,5] For example, pandamarilactone-1 and pandamarine were isolated from the leaves of *Pandanus amaryllifolius*;[6] solasodine and its derivatives were isolated from *Solanum umbelliferum*, which exhibited significant activity toward DNA repair-deficient yeast mutants;[7] azaspiracids are marine phycotoxins isolated from cultivated mussels in Killary harbor, Ireland;[8] and chlorofusin A is a novel fungal metabolite showing the potential as a lead in cancer therapy.[9] In addition, aza-spiropyrans **C**, being able to equilibrate with the corresponding non-spiro analogue **D**, is a well known class of compounds possessing photochromic properties for use in the area of photochemical erasable memory,[10] and also found applications as self-development photography, actinometry, displays, filters, lenses of variable optical density,[11] and photomechanical biomaterials etc.[12]



Scheme 1: The skeletons of useful aza-spiroketals and some naturally occurring hydroxylated indolizidines.

On the other hand, hydroxylated indolizidines [13-20] such as castanospermine, (−)-swainsonine, (+)-lentiginosine (**1**) [21-23] and (−)-2-epilentiginosine (**2**) [21-26] constitute a class of azasugars showing potent and selective glycosidase inhibitory activities. [13-20] (1*R*,8a*S*)-1-Hydroxyindolizidine **3** has been postulated as a biosynthetic precursor [21-26] of (+)-lentiginosine (**1**), (−)-2-epilentiginosine (**2**) and (−)-swainsonine, a potentially useful antimetastasis drug for the treatment of cancer.[15] In addition, these molecules serve as platforms for testing synthetic strategies, and several asymmetric syntheses of both enantiomers of 1-hydroxyindolizidine (**3**) have been reported. [27-34]In continuation of our efforts in the development of enantiomeric malimide-based synthetic methodologies, [35-38] we now report concise and highly diastereoselective syntheses of an aza-spiropyran derivative **7** and (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**).

Results and discussion

Previously, we have shown that the addition of Grignard reagents to *N*,*O*-dibenzyl malimide (**4**) leads to *N*,*O*-acetals **5** in high regioselectivity (Scheme 2), and the subsequent reductive dehydroxylation gives **6** in high *trans*-diastereoselectivity.[35] On the other hand, treatment of *N*,*O*-acteals **5** with an acid furnished enamides **E**, which can be transformed stereoselectively to either hydroxylactams **F** or **G** under appropriate conditions. [36-38] It was envisioned that if a C_4-bifunctional Grignard reagent was used, both aza-spiroketal **H** (such as aza-spiropyran, n = 1, path a) and indolizidine ring systems **I** (path b) could be obtained.

The synthesis of aza-spiropyran **7** started from the Grignard addition of malimide **4**. Treatment of the THP-protected 4-hydroxybutyl magnesium bromide with malimide **4** at −20°C for 2.5 h afforded *N*,*O*-acetal **5a** as an epimeric mixture in 7:1 ratio and with a combined yield of 89% (Scheme 3). If the reaction was allowed to stir at room temperature overnight, the diastereomeric ratio was inversed to 1: 1.8. Subjection of the diastereomeric mixture of the *N*,*O*-acetal **5a** to acidic condi-



Scheme 2: Synthetic strategy based on *N*,*O*-dibenzylmalimide (**4**).



Scheme 3: Stereoselectivity synthesis of aza-spiropyran **7**.

tions [TsOH (cat.)/CH_2Cl_2, r.t.] for 0.5 h resulted in the formation of the desired functionalized aza-spiropyran derivative **7** as a single diastereomer in quantitative yield. The result means that a tandem dehydration-THP cleavage-intramolecular nucleophilic addition occurred. When the stirring was prolonged to 2 h, about 5% of another epimer (no shown) was also formed according to the ^{1}H NMR analysis.

The stereochemistry of the aza-spiropyran **7** was determined on the basis of the NMR analysis. This was done firstly by a ^{1}H-^{1}H COSY experiment to confirm the proton assignments, and then by NOESY experiment. As shown in Figure 1, the strong NOE correlation of H-9a (δ_H 3.59) and H-4 (δ_H 4.22) indicates clearly O_4/O_5-*trans* relationship in compound **7**.

These findings are surprising comparing with our recent observations. In our previous investigations, it was observed that the treatment of *N*,*O*-acetals **5** with an acid leads to the dehydration products **E** (Scheme 2), and the two diastereomers of **5** shows different reactivities towards the acid-promoted dehydration. [36-38] The *trans*-diastereomer reacts much more slower than the *cis*-diastereomer, and some un-reacted *trans*-epimer was



Figure 1: The observed NOE correlations (in part) and the region expanded NOESY spectrum of compound **7**.



Scheme 4: Stereoselective synthesis of (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**).

always recovered even starting with a pure *cis*-diastereomer. In the present study, not only both two diastereomers have been completely converted to the aza-spiropyran **7**, what is equally surprising is that no dehydration product was observed under acidic conditions!

For the synthesis of *ent*-**3**, aza-spiropyran **7**, a cyclic *N*,*O*-acetal, was converted to lactam **6a** under standard reductive dehydroxylation conditions (Et_3SiH, $BF_3{\cdot}OEt_2$, −78°C, 6 h; warm-up, yield: 78%) (Scheme 4). Under the same conditions, *N*,*O*-acetal **5a** was converted to lactam **6a** in 77% yield. It was observed that during the reaction of **5a**, **7** was first formed as an intermediate after the addition of Et_3SiH and $BF_3{\cdot}OEt_2$, and stirring for 1 hour.

Reduction of lactam **6a** with borane-dimethylsulfide provided pyrrolidine derivative **8** in 95% yield. Compound **8** was then converted to (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**) {$[\alpha]_D^{27}$ +50 (*c* 0.90, EtOH); lit.[29] $[\alpha]_D$ +51.0 (*c* 0.54, EtOH); lit.[32] −49.7 (*c* 0.95, EtOH) for the antipode} via a four-step procedure, namely, one-pot *N*-debenzylation-*N*-Boc formation/*O*-mesylation/Boc-cleavage/cyclication, and *O*-debenzylation.

In searching for a more concise method, amino alcohol **8** was mesylated (MsCl, NEt_3, 0 °C) and the resultant labile mesylate **12** was subjected to catalytic hydrogenolysis (H_2, 1 atm, 10% Pd/C, r.t.), which gave (1*S*,8a*R*)-1-hydroxyindolizidine (*ent*-**3**) in 60% overall yield from **8** (Scheme 5).[39,40] The one-pot *N*,*O*-bis-debenzylation and cyclization of mesylate **12** deserves comment. Because the *N*-debenzylation generally required longer reaction time,[41] or using of Pearlman's catalyst (cf. Scheme 4). The easy debenzylation of **12** allows assuming that an intramolecular substitution occurred firstly, and the formation of the quaternary ammonium salt **K** [40] then favors the reductive debenzylation. This mechanism is supported by the following observations. First, in a similar case, Thompson et al observed that the formation of a mesylate resulted in spontaneous quarternization leading to the bicyclic indolizidine.[40] Second, we have also observed that the tosylate of **8** is too labile to be isolated, and mesylate **12** decomposed upon flash column chromatography on silica gel, which are due to the spontaneous formation of a polar quaternary ammonium salt. In addition, the presence of the *O*-benzyl group in **K** is an assumption based on our previous observation on a similar case.[42]



Scheme 5: One-pot synthesis of *ent*-**3** from amino alcohol **8**.

Conclusion

In summary, we have demonstrated that by the reaction of functionalized Grignard reagent with the protected (*S*)-malimide **4**, either aza-spiropyran derivative **7** or (1*S*,8a*R*)-1-hydroxyindolizidine skeleton (*ent*-**3**) can be constructed in a concise and selective manner. It is worthy of mention that in addition to the reductive dehydroxylation leading to 2-pyrrolidinones **6**, and

the acid-promoted dehydration leading to (*E*)-enamides **E** (and then **F**, **G**), acid treatment of the *N*,*O*-acetal **5a** could provide, chemoselectively and quantitatively, the aza-spiropyran ring system **7**. The results presented herein constitute a valuable extension of our malimides-based synthetic methodology.

See Supporting Information File 1 for full experimental procedures and characterization data of the synthesized compounds.

Supporting Information

Supporting Information File 1

Experimental. Experimental procedures for the synthesis of all compounds described, and characterization data for the synthesized compounds.
[http://www.beilstein-journals.org/bjoc/content/supplementary/1860-5397-3-41-S1.doc]

Acknowledgments

The authors are grateful to the NSFC (20572088), NSF of Fujian Province and Xiamen City (2006J0268; 3502z20055019) and the program for Innovative Research Team in Science & Technology (University) in Fujian Province for financial support. We thank Professor Y. F. Zhao for the use of her Bruker Dalton Esquire 3000 plus LC-MS apparatus.

References

1. Perron, F.; Albizati, K. M. *Chem. Rev.* **1989,** *89,* 1617–1661. doi:10.1021/cr00097a015
2. Boivin, T. L. B. *Tetrahedron* **1987,** *43,* 3309–3362. doi:10.1016/S0040-4020(01)81626-4
3. Brimble, M. A.; Farès, F. A. *Tetrahedron* **1999,** *55,* 7661–7706. doi:10.1016/S0040-4020(99)00387-7
4. Nonato, M. G.; Garson, M. J.; Truscott, R. J. W.; Carver, J. A. *Phytochemistry* **1993,** *34,* 1159–1163. doi:10.1016/S0031-9422(00)90735-0
5. Byrne, L. T.; Guevara, B. Q.; Patalinghug, W. C.; Recio, B. V.; Ualat, C. R.; White, A. H. *Aust. J. Chem.* **1992,** *45,* 1903–1908.
6. Pradhan, R.; Patra, M.; Behera, A. K.; Mishra, B. K.; Behera, R. K. *Tetrahedron* **2006,** *62,* 779–828. doi:10.1016/j.tet.2005.09.039
7. Kim, Y. C.; Che, Q. M.; Gunatilake, A. A. L.; Kingston, D. G. I. *J. Nat. Prod.* **1996,** *59,* 283–285. doi:10.1021/np960125a
8. Satake, M.; Ofuji, K.; Naoki, H.; James, K. J.; Furey, A.; McMahon, T.; Silke, J.; Yasumoto, T. *J. Am. Chem. Soc.* **1998,** *120,* 9967–9968. doi:10.1021/ja981413r
9. Duncan, S. J.; Gruschow, S.; Williams, D. H.; McNicholas, C.; Purewal, R.; Hajek, M.; Gerlitz, M.; Martin, S.; Wrigley, S.; Moore, M. *J. Am. Chem. Soc.* **2001,** *123,* 554–560. doi:10.1021/ja002940p
10. Fisher, E.; Hirshberg, Y. *J. Chem. Soc.* **1952,** 4522–4524.
11. Berkovic, G.; Krongauz, V.; Weiss, V. *Chem. Rev.* **2000,** *100,* 1741–1754. doi:10.1021/cr9800715
12. McCoy, C. P.; Donnelly, L.; Jones, D. S.; Gorman, S. P. *Tetrahedron Lett.* **2007,** *48,* 657–661. doi:10.1016/j.tetlet.2006.11.110
13. Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. J. *Tetrahedron: Asymmetry* **2000,** *11,* 1645–1680. doi:10.1016/S0957-4166(00)00113-0
14. Ahmed, E. N. *Tetrahedron* **2000,** *56,* 8579–8629. doi:10.1016/S0040-4020(00)00178-2
15. Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. *Phytochemistry* **2001,** *56,* 265–295. doi:10.1016/S0031-9422(00)00451-9
16. Michael, J. P. *Nat. Prod. Rep.* **2000,** *17,* 579–602. doi:10.1039/a904849i
17. Michael, J. P. *Nat. Prod. Rep.* **2001,** *18,* 520–542. doi:10.1039/b005384h
18. Michael, J. P. *Nat. Prod. Rep.* **2003,** *20,* 458–475. doi:10.1039/b208137g
19. Michael, J. P. *Nat. Prod. Rep.* **2004,** *21,* 625–649. doi:10.1039/b310689f
20. Michael, J. P. *Nat. Prod. Rep.* **2005,** *22,* 603–626. doi:10.1039/b413748p
21. Pastuszak, I.; Molyneux, R. J.; James, L. F.; Elbein, A. D. *Biochemistry* **1990,** *29,* 1886–1891. doi:10.1021/bi00459a032
22. Rasmussen, M. O.; Delair, P.; Greene, A. E. *J. Org. Chem.* **2001,** *66,* 5438–5443. doi:10.1021/jo010298r
    For recent asymmetric syntheses of lentiginosine, see [22,23]
23. Ha, D.-C.; Yun, C.-S.; Lee, Y. *J. Org. Chem.* **2000,** *65,* 621–623. doi:10.1021/jo9913762
24. Harris, T. M.; Harris, C. M.; Hill, J. E.; Ungemach, F. S.; Broquist, H. P.; Wickwire, B. M. *J. Org. Chem.* **1987,** *52,* 3094–3098. doi:10.1021/jo00390a024
25. Harris, C. M.; Campbell, B. C.; Molyneux, R. J.; Harris, T. M. *Tetrahedron Lett.* **1988,** *29,* 4815–4818. doi:10.1016/S0040-4039(00)80616-4
26. Harris, C. M.; Schneider, M. J.; Ungemach, F. S.; Hill, J. E.; Harris, T. M. *J. Am. Chem. Soc.* **1988,** *110,* 940–949. doi:10.1021/ja00211a039
27. Aaron, H. S.; Pader, C. P.; Wicks, G. E., Jr. *J. Org. Chem.* **1966,** *31,* 3502–3505. doi:10.1021/jo01349a008
    For the synthesis of racemic 1-hydroxyindolizidine, see [27,28]
28. Clevenstine, E. C.; Walter, P.; Harris, T. M.; Broquist, H. P. *Biochemistry* **1979,** *18,* 3663–3667. doi:10.1021/bi00584a004
29. Harris, C. M.; Harris, T. M. *Tetrahedron Lett.* **1987,** *28,* 2559–2562. doi:10.1016/S0040-4039(00)96147-1
    For the asymmetric synthesis of (1*S*,8a*R*)-1-hydroxyindolizidine, see [29,30]
30. Klitzke, C. F.; Pilli, R. A. *Tetrahedron Lett.* **2001,** *42,* 5605–5608. doi:10.1016/S0040-4039(01)01084-X
31. Shono, T.; Kise, N.; Tanabe, T. *J. Org. Chem.* **1988,** *53,* 1364–1367. doi:10.1021/jo00242a004
    For the asymmetric synthesis of (1*R*,8a*S*)-1-hydroxyindolizidine, see [29-34]
32. Takahata, H.; Banba, Y.; Momose, T. *Tetrahedron: Asymmetry* **1990,** *1,* 763–764. doi:10.1016/S0957-4166(00)80440-1
33. Guerreiro, P.; Ratovelomanana-Vidal, V.; Genêt, J. P. *Chirality* **2000,** *12,* 408–410. doi:10.1002/(SICI)1520-636X(2000)12:5/6<408::AID-CHIR20>3.0.CO;2-G
34. Rasmussen, M. O.; Delair, P.; Greene, A. E. *J. Org. Chem.* **2001,** *66,* 5438–5443. doi:10.1021/jo010298r
35. Huang, P.-Q. *Synlett* **2006,** 1133–1149. doi:10.1055/s-2006-941565
36. Zhou, X.; Huang, P.-Q. *Synlett* **2006,** 1235–1239. doi:10.1055/s-2006-939695
37. Zhou, X.; Zhang, P.-Y.; Ye, J.-L.; Huang, P.-Q. *C. R. Chim.*, in press. doi:10.1016/j.crci.2007.02.018

38. Zhou, X.; Liu, W.-J.; Ye, J.-L.; Huang, P.-Q. *J. Org. Chem.* **2007,** *72,* 8904–8909. doi:10.1021/jo7018784
39. Ikota, N.; Hanaki, A. *Heterocycles* **1987,** *26,* 2369–2370.
40. Gren, D. L. C.; Kiddle, J. J.; Thompson, C. M. *Tetrahedron* **1995,** *51,* 2865–2874. doi:10.1016/0040-4020(95)00037-9
41. Liu, L.-X.; Ruan, Y.-P.; Guo, Z.-Q.; Huang, P.-Q. *J. Org. Chem.* **2004,** *69,* 6001–6009. doi:10.1021/jo049166z
42. Huang, P.-Q.; Meng, W.-H. *Tetrahedron: Asymmetry* **2004,** *15,* 3899–3910. doi:10.1016/j.tetasy.2004.05.037

License and Terms